Baxter has entered an exclusive distribution agreement with BioMerieux for the latter's NEPHROCLEAR CCL14 test, a kidney injury diagnostic test that is in development. Baxter will be the test's exclusive distributor in the US and Europe.
Qiagen has bought the remaining 80.1% of diagnostics instrument firm NeuMoDx for $248 million in cash, after purchasing a 19.9% stake in 2018. "NeuMoDx has built an unparalleled platform that has demonstrated superior value during the coronavirus pandemic. This will expand Qiagen's portfolio of automated testing solutions and provide another driver for future growth," Qiagen CEO Thierry Bernard said.
The Panbio COVID-19 Ag Rapid Test has been released by Abbott in France. "This rapid and portable nasopharyngeal swab test device is a very useful tool for supporting public health strategies in France, such as contact case tracing and large-scale testing campaigns across France," Abbott France Sales Director Jean-Baptiste Nivet said.
The Elecsys Anti-SARS-CoV-2 S antibody test has been released by Roche. "The new quantitative Elecsys antibody test can play a pivotal role in vaccine clinical trials as well as helping clinicians assess patients' immune response," said CEO Thomas Schinecker.
Hoth Therapeutics and the George Washington University will collaborate to develop an in vitro nanohole array-based diagnostic device that uses a plasmonic system to immediately detect SARS-CoV-2 using a mobile device.
Researchers in France found that SARS-CoV-2 infection was associated with an increased rate of Kawasaki disease in youths. The findings, published in The Lancet Child and Adolescent Health, also showed that those with severe Kawasaki disease were more likely to require admission to the intensive care unit, need combination therapy with inotrope treatment and have myocarditis.
European regulators have given CE mark approval to DiaSorin for its Simplexa COVID-19 Direct assay for the testing of saliva samples to identify people with COVID-19.
The Biomedical Advanced Research and Development Authority has given $12.85 million to Ortho Clinical Diagnostics to aid in the development of its COVID-19 antigen test and to help obtain regulatory clearance for its total and IgG antibody tests that have received emergency use authorization.
